These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 15486519)

  • 1. Neuroprotection in Huntington's disease: a 2-year study on minocycline.
    Bonelli RM; Hödl AK; Hofmann P; Kapfhammer HP
    Int Clin Psychopharmacol; 2004 Nov; 19(6):337-42. PubMed ID: 15486519
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Minocycline in Huntington's disease: a pilot study.
    Thomas M; Ashizawa T; Jankovic J
    Mov Disord; 2004 Jun; 19(6):692-5. PubMed ID: 15197710
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Riluzole in Huntington's disease (HD): an open label study with one year follow up.
    Seppi K; Mueller J; Bodner T; Brandauer E; Benke T; Weirich-Schwaiger H; Poewe W; Wenning GK
    J Neurol; 2001 Oct; 248(10):866-9. PubMed ID: 11697523
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Revisiting safety of minocycline as neuroprotection in Huntington's disease.
    Reynolds N
    Mov Disord; 2007 Jan; 22(2):292. PubMed ID: 17083098
    [No Abstract]   [Full Text] [Related]  

  • 5. Minocycline safety and tolerability in Huntington disease.
    Huntington Study Group
    Neurology; 2004 Aug; 63(3):547-9. PubMed ID: 15304592
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of Participant Withdrawal in Huntington Disease Clinical Trials.
    Banno H; Andrzejewski KL; McDermott MP; Murphy A; Majumder M; de Blieck EA; Auinger P; Cudkowicz ME; Atassi N
    J Huntingtons Dis; 2017; 6(2):149-156. PubMed ID: 28671136
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Deleterious effects of minocycline in animal models of Parkinson's disease and Huntington's disease.
    Diguet E; Fernagut PO; Wei X; Du Y; Rouland R; Gross C; Bezard E; Tison F
    Eur J Neurosci; 2004 Jun; 19(12):3266-76. PubMed ID: 15217383
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Apoptotic cascades as possible targets for inhibiting cell death in Huntington's disease.
    Pattison LR; Kotter MR; Fraga D; Bonelli RM
    J Neurol; 2006 Sep; 253(9):1137-42. PubMed ID: 16998646
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Minocycline modulates neuroprotective effect of hesperidin against quinolinic acid induced Huntington's disease like symptoms in rats: behavioral, biochemical, cellular and histological evidences.
    Kumar A; Chaudhary T; Mishra J
    Eur J Pharmacol; 2013 Nov; 720(1-3):16-28. PubMed ID: 24211676
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exercise effects in Huntington disease.
    Frese S; Petersen JA; Ligon-Auer M; Mueller SM; Mihaylova V; Gehrig SM; Kana V; Rushing EJ; Unterburger E; Kägi G; Burgunder JM; Toigo M; Jung HH
    J Neurol; 2017 Jan; 264(1):32-39. PubMed ID: 27747393
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cognitive function in early clinical phase huntington disease after rivastigmine treatment.
    Sešok S; Bolle N; Kobal J; Bucik V; Vodušek DB
    Psychiatr Danub; 2014 Sep; 26(3):239-48. PubMed ID: 25191771
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Minocycline is not beneficial in a phenotypic mouse model of Huntington's disease.
    Diguet E; Rouland R; Tison F
    Ann Neurol; 2003 Dec; 54(6):841-2. PubMed ID: 14681898
    [No Abstract]   [Full Text] [Related]  

  • 13. Riluzole in Huntington's disease: a 3-year, randomized controlled study.
    Landwehrmeyer GB; Dubois B; de Yébenes JG; Kremer B; Gaus W; Kraus PH; Przuntek H; Dib M; Doble A; Fischer W; Ludolph AC;
    Ann Neurol; 2007 Sep; 62(3):262-72. PubMed ID: 17702031
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Minocycline and other tetracycline derivatives: a neuroprotective strategy in Parkinson's disease and Huntington's disease.
    Thomas M; Le WD; Jankovic J
    Clin Neuropharmacol; 2003; 26(1):18-23. PubMed ID: 12567160
    [No Abstract]   [Full Text] [Related]  

  • 15. A futility study of minocycline in Huntington's disease.
    Huntington Study Group DOMINO Investigators
    Mov Disord; 2010 Oct; 25(13):2219-24. PubMed ID: 20721920
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data.
    Tabrizi SJ; Scahill RI; Owen G; Durr A; Leavitt BR; Roos RA; Borowsky B; Landwehrmeyer B; Frost C; Johnson H; Craufurd D; Reilmann R; Stout JC; Langbehn DR;
    Lancet Neurol; 2013 Jul; 12(7):637-49. PubMed ID: 23664844
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The functional implications of motor, cognitive, psychiatric, and social problem-solving states in Huntington's disease.
    Van Liew C; Gluhm S; Goldstein J; Cronan TA; Corey-Bloom J
    Psychiatry; 2013; 76(4):323-35. PubMed ID: 24299091
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Creatine supplementation lowers brain glutamate levels in Huntington's disease.
    Bender A; Auer DP; Merl T; Reilmann R; Saemann P; Yassouridis A; Bender J; Weindl A; Dose M; Gasser T; Klopstock T
    J Neurol; 2005 Jan; 252(1):36-41. PubMed ID: 15672208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Minocycline is protective in a mouse model of Huntington's disease.
    Hersch S; Fink K; Vonsattel JP; Friedlander RM
    Ann Neurol; 2003 Dec; 54(6):841; author reply 842-3. PubMed ID: 14681897
    [No Abstract]   [Full Text] [Related]  

  • 20. Combination therapy using minocycline and coenzyme Q10 in R6/2 transgenic Huntington's disease mice.
    Stack EC; Smith KM; Ryu H; Cormier K; Chen M; Hagerty SW; Del Signore SJ; Cudkowicz ME; Friedlander RM; Ferrante RJ
    Biochim Biophys Acta; 2006 Mar; 1762(3):373-80. PubMed ID: 16364609
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.